CompletedNot Applicable

Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients

South Korea3,422 participantsStarted 2012-01-05

Plain-language summary

This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * living donor liver transplantation recipients (≥18 years) Exclusion Criteria: * preoperative serum creatinine (sCr) \> 1.4 mg/dL, diagnosed CKD or hepatorenal syndrome (HRS), or hemodialysis at baseline

What they're measuring

acute kidney injury

Timeframe: within 7 days after surgery

Trial details

NCT IDNCT06340607

SponsorAsan Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-01-05

View on ClinicalTrials.gov More Acute Kidney Injury trials